Pitcairn Co. Decreases Holdings in Pfizer Inc. (NYSE:PFE)

Pitcairn Co. reduced its position in Pfizer Inc. (NYSE:PFE) by 21.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 20,677 shares of the biopharmaceutical company’s stock after selling 5,592 shares during the quarter. Pitcairn Co.’s holdings in Pfizer were worth $549,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in PFE. United Bank increased its holdings in shares of Pfizer by 3.7% during the third quarter. United Bank now owns 35,599 shares of the biopharmaceutical company’s stock valued at $1,030,000 after acquiring an additional 1,277 shares in the last quarter. Janus Henderson Group PLC raised its holdings in shares of Pfizer by 0.5% in the third quarter. Janus Henderson Group PLC now owns 530,429 shares of the biopharmaceutical company’s stock worth $15,348,000 after buying an additional 2,600 shares during the last quarter. Kovitz Investment Group Partners LLC lifted its stake in shares of Pfizer by 35.4% during the third quarter. Kovitz Investment Group Partners LLC now owns 366,690 shares of the biopharmaceutical company’s stock worth $10,612,000 after buying an additional 95,896 shares during the period. Hendershot Investments Inc. grew its holdings in shares of Pfizer by 12.7% during the third quarter. Hendershot Investments Inc. now owns 24,895 shares of the biopharmaceutical company’s stock valued at $720,000 after buying an additional 2,798 shares during the last quarter. Finally, DF Dent & Co. Inc. raised its stake in Pfizer by 11.9% in the 3rd quarter. DF Dent & Co. Inc. now owns 45,708 shares of the biopharmaceutical company’s stock worth $1,323,000 after acquiring an additional 4,852 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the stock in a transaction dated Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.06% of the stock is currently owned by company insiders.

Pfizer Stock Down 5.4 %

Shares of PFE opened at $22.99 on Friday. The stock has a fifty day simple moving average of $25.87 and a two-hundred day simple moving average of $26.74. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $130.39 billion, a PE ratio of 16.31, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. Pfizer Inc. has a 52-week low of $22.95 and a 52-week high of $31.54.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.10 earnings per share. As a group, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Truist Financial dropped their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. UBS Group reduced their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Finally, Bank of America reissued a “neutral” rating and set a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.